Related Experiment Video
Updated: May 4, 2026
08:52
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
9.8K
The pertussis problem
1Department of Pediatrics, University of Pennsylvania, Philadelphia.
Insights
Pertussis is increasing in vaccinated children. Waning immunity from acellular vaccines is a key issue, prompting a discussion on vaccine improvements.
Area of Science:
- Immunology
- Vaccinology
- Infectious Diseases
Background:
- Pertussis (whooping cough) is experiencing a resurgence globally.
- A significant number of cases are reported in vaccinated children and adolescents.
- Waning immunity following immunization is a suspected contributing factor.
Purpose of the Study:
- To address the challenge of resurgent pertussis in vaccinated populations.
- To explore the role of waning immunity in the ineffectiveness of current vaccines.
- To discuss potential strategies for improving acellular pertussis vaccines.
Main Methods:
- Literature review and analysis of pertussis epidemiology.
- Examination of immunological data related to vaccine efficacy and duration.
- Discussion of potential vaccine design modifications and adjuvant strategies.
Main Results:
- Acellular pertussis vaccines demonstrate a decline in protective immunity over time.
- The duration of protection appears shorter than with older whole-cell vaccines.
- Breakthrough infections in vaccinated individuals highlight the need for enhanced vaccine strategies.
Conclusions:
- Waning immunity is a significant factor in the current pertussis resurgence.
- Improvements in acellular vaccine formulations are necessary to extend protection duration.
- Further research into novel vaccine platforms and boosting strategies is warranted.
Abstract:
Pertussis is resurgent, and many cases are occurring in vaccinated children and adolescents. In countries using acellular vaccines, waning immunity is at least part of the problem. This article discusses possible improvements in those vaccines.
Related Concept Videos
01:28Diphtheria
175
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
175
01:30Pneumonia III: Complications and Assessment
1.4K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
01:14Atypical Pneumonia
84
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
01:17Pulmonary Cycle: Exhalation
5.2K
In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
5.2K
01:29Pneumonia II: Pathophysiology
4.7K
The pathophysiology of pneumonia involves the following steps:
4.7K
01:29Pneumonia I: Introduction
24
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24